SANTA CLARA, Calif., May 3 /PRNewswire/ -- Abmaxis, Inc., a privately held biopharmaceutical company, announced today that CJ Wang, Ph.D., has joined the company as Vice President, Business Development, a new position. Dr. Wang brings with him 15 years experience in the pharmaceutical and biotechnology industry, most recently as Vice President of Business Development of TaiGen Biotechnology Co., Ltd., an Asian research and development company funded by major US venture capital and Asian financial institutions.
"We are very pleased to have someone with CJ's business experience and scientific credentials join us to develop and expand our strategic planning and corporate partnering programs; and to build upon the successful collaborations we have created thus far," stated Shirley Liu Clayton, Chief Executive Officer of Abmaxis, Inc.
"I believe that CJ's unique background in working with companies in the US and Asia should help Abmaxis' strategic presence in Asia, where there is increasing interest in antibody drug products and for advanced technology for monoclonal antibody development," added Peter Luo, Abmaxis Co-founder and Chief Technical Officer.
Prior to TaiGen, Dr. Wang was Vice President of Business Development and Marketing at Cellomics, Inc., a leader in developing and commercializing technology platforms for automated cell analysis, which is widely used in high-content screening (HCS) by the global pharmaceutical and biotech industry for drug discovery and development. Previously, he built a successful track record at Packard Bioscience in marketing, business development and product development as Director of Licensing, Acquisition and Alliances; Director of AlphaScreen Technology and Systems; and Marketing Manager for high-throughput screening (HTS) product lines. Dr. Wang began his career in the pharmaceutical industry as a senior scientist at Schering-Plough, conducting drug discovery and development projects in several therapeutic areas. He holds a Ph.D. in Pharmaceutical Sciences from the College of Pharmacy, University of Kentucky.
Abmaxis is a privately held biopharmaceutical company based in Santa Clara, California, specializing in monoclonal antibody discovery, humanization and optimization for therapeutic, diagnostic and research use. Abmaxis has built a proprietary and robust technology platform, Abmaxis' In-silico Immunization (AISIM(TM)), which dramatically shifts the antibody-engineering paradigm to accelerate antibody drug discovery and optimization processes. Abmaxis has generated and optimized over a dozen antibody candidates in multiple therapeutic areas, such as cancer, inflammatory diseases and infectious diseases, for its partners and for its own pipeline. These antibodies are fully humanized, expressed with excellent yields and stability, and have high affinities suitable for therapeutic applications. Applying AISIMTM, the company discovers human antibodies, converts murine to human antibodies and optimizes humanized monoclonal antibodies for desired therapeutic properties such as affinity, specificity, stability, effectors functions, etc. Abmaxis' scientists are experts in their ability to design antibodies that are customized for specific functions. The company is actively pursuing partnerships with pharmaceutical and biotech companies for human antibody discovery, optimization and co-development. For more information please visit the web site at http://www.abmaxis.com/. For partnering opportunities, please contact CJ Wang at 408-988-6100, x101 or email@example.com.